Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Abstract Background Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is limited by acquired resistance driven by the EGFR T790M mutation. The discovery of third-generation EGFR inhib...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Tao Zhang, Rong Qu, Shingpan Chan, Mengzhen Lai, Linjiang Tong, Fang Feng, Hongyu Chen, Tingting Song, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Yanyan Shen, Yiming Sun, Yi Chen, Meiyu Geng, Ke Ding, Jian Ding, Hua Xie
Format: Artigo
Idioma:Inglês
Publicat: BMC 2020-05-01
Col·lecció:Molecular Cancer
Matèries:
Non-small cell lung cancer (NSCLC)
EGFR T790M
Small-molecule inhibitor
Drug resistance
Ack1
Accés en línia:http://link.springer.com/article/10.1186/s12943-020-01202-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars